

Date: 17/04/2024
Your Ref:
Our Ref: 8562

Enquiries to : Richard Mutch
Extension: 35687
Direct Line: 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – ADULT ADHD ASSESSMENT

I write in response to your request for information in relation to Adult ADHD Assessment within NHS Lothian.

Question:

1. Please provide the following data relating to both "NHS Lothian" and NHS Scotland as a whole. The wait times from referral to appointment for "Adult ADHD Assessment" for the last 5 years.

Answer:

Year seen (removed from list)	NHS Lothian Average of Weeks Waiting
2019	76.8
2020	66.9
2021	91.0
2022	87.1
2023	119.3

Please note that we can only provide details for NHS Lothian and not for Scotland as a whole.

Question:

2. Please provide the following data relating to both NHS Lothian and NHS Scotland as a whole. The current, and historic (5 years expressed yearly) availability of ADHD medication as licensed, and where there is no availability, the expected restocking period. To include: methylphenidate lisdexamfetamine dexamfetamine atomoxetine guanfacine

Answer:

See enclosed.

Please note that we can only provide details for NHS Lothian and not for Scotland as a whole.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing, Midwifery and AHPs
Cc: Chief Executive
Enc.

	National alerts	Lothian (secondary care)	National alerts	Lothian (secondary care)	National alerts	Lothian (secondary care)	National alerts	Lothian (secondary care)	National alerts	Lothian (secondary care)
Methylphenidate	<p>NatPSA/2023/011/DHSC (issued 27/9/23) Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets. Expected to resolve at various dates between October and December 2023.</p>	Intermittent supply issues	<p>MSN/2022/050 Methylphenidate (Xaggitin® XL) 18mg, 27mg, 36mg and 54mg prolonged-release tablets 18mg, 27mg and 36mg prolonged-release tablets are out of stock until mid-June 2022 and 54mg prolonged-release tablets are out of stock until mid-July 2022.</p>	Intermittent supply issues		No supply issue experienced		No supply issue experienced	<p>MSAN(2019)11 Medicine Supply Alert Notice: medicine/drug in short supply: Delmosart® (methylphenidate) 18mg prolonged-release tablets Anticipated to resolve by 15/11/19</p>	No supply issue experienced

Lisdexamfetamine	NatPSA/2023/011/DHSC (issued 27/9/23) Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets. Expected to resolve at various dates between October and December 2023.	Intermittent supply issues	MSAN(2024)06 Lisdexamfetamine (Elvanse®) capsules There will be intermittent supply of all strengths of lisdexamfetamine (Elvanse®) capsules until April 2024.			No supply issue experienced		No supply issue experienced		No supply issue experienced
	MSN/2024/019 Lisdexamfetamine (Elvanse®) capsules Intermittent supply of all strengths until April 2024. • Supplies of various strengths of Elvanse® will be available at different times throughout this period.									
Dexamfetamine		No supply issue experienced		No supply issue experienced		No supply issue experienced		No supply issue experienced		No supply issue experienced
Atomoxetine	MSAN(2023)13 Atomoxetine 40mg and 60mg capsules Out of stock from late July 2023 until	Intermittent supply issues, ULM atomoxetine		No supply issue experienced		No supply issue experienced		No supply issue experienced		No supply issue experienced

	September 2023.	40mg capsules – issued October 23							
	MSN/2023/068 Atomoxetine 40mg and 60mg capsules 40mg and 60mg capsules will be out of stock from late July 2023 until September 2023.								
	NatPSA/2023/011/DHSC (issued 27/9/23) Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets. Expected to resolve at various dates between October and December 2023.								
Guanfacine	NatPSA/2023/011/DHSC (issued 27/9/23) Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-	Intermittent supply issues, ULM guanfacine 1mg MR/ 2mg MR issued in		No supply issue experienced		No supply issue experienced		No supply issue experienced	No supply issue experienced

